Farmas USA

TGTX

Los datos del poster que presenta hoy:

http://ir.tgtherapeutics.com/releasedetail.cfm?ReleaseID=974423

Activity:

At the Phase 3 dose of 800mg, the following responses were observed:
88% (14/16) ORR in patients with CLL including 2 CR's (one of which was a 17p del) plus a PR in an ibrutinib refractory patient
57% (4/7) ORR in patients with DLBCL with compelling activity observed in GCB subtype
53% (9/17) ORR in patients with follicular and marginal zone lymphoma (iNHL)
ORR in iNHL for patients treated at higher doses (1200mg of the initial formulation or ≥600 mg of the micronized formulation), was not only greater with the TG-1303 combination (55%) as opposed to monotherapy with TGR-1202 (41%), but the depth of response was significantly greater with the combination (CR rate of 5% for monotherapy vs. 30% for the TG-1303 combination)
Three (3) Complete Responses were observed in patients with DLBCL treated at higher doses of TGR-1202 in combination with TG-1101, 2 of which were of GCB subtype, supporting our UNITY-DLBCL Phase 2b design
25% ORR in ibrutinib refractory patients, highlighting the challenge of treating patients that break through ibrutinib therapy and the potential risks of initiating ibrutinib therapy early

ADXS

Durable complete response seen in a recurrent / metastatic cervical cancer patient previously treated with chemoradiation and systemic-dose chemotherapy plus bevacizumab

GOG/NRG-0265 is a single-arm two-stage, Phase 2 multicenter study (NCT01266460). Stage 1 of the trial enrolled 26 AXAL-treated patients who received up to three doses at 1x109 colony forming units administered in 28 day intervals. Results from Stage 1 demonstrated a twelve-month survival rate of 38.5 percent, which exceeds prior historical GOG trials in this patient population. The twelve-month survival rate among the 69 percent of patients who received the maximum three per protocol doses was 56 percent, with a 12.1-month median overall survival. Safety and efficacy results of Stage 1 met the criteria for the initiation of Stage 2, which was amended for continuous cycles of AXAL (greater than three doses).

Buenos datos, pero tienen que rehacer un grupo por la discontinuación del estudio. Dicen que comenzará en breve.

Given the substantial proportion of Stage 2 patients that discontinued treatment with AXAL as a result of the clinical hold, Advaxis and the GOG/NRG agreed to re-enroll a new cohort of Stage 2 patients. The re-enrollment of Stage 2 is expected to commence shortly.

http://ir.advaxis.com/press-releases/detail/1223/advaxis-announces-updated-data-at-asco-from-a-phase-2-study

ONTY

Jefferies maintained Oncothyreon (ONTY) coverage with Buy and target $4

Pues nada, he reducido el 36% de mi carga en NVAX.

A la espera de ver donde recargo y si no me deja hacerlo entre 5,5-5,65 pues bueno, aun llevo la carga inicial a 7,2 y algo le sacare a todo aquello.

NVAX

Artículo sobre ganadores y perdedores en el ASCO del Bastardo

Sobre ONTY alaba sus buenos datos pero dice que los inversores no confían en ella por su mala gestión.

Winner/Loser: For the second consecutive ASCO meeting, Oncothyreon's (ONTY) HER-2 targeted breast cancer drug ONT-380 delivers strong clinical data. But the stock is down 70% from last year because investors lack confidence in the company's management team, balance sheet and its ability to develop ONT-380 successfully. Oncothyreon is desperate for an experienced partner.

https://www.thestreet.com/story/13597010/2/cancer-drug-stocks-the-winners-and-losers-from-asco-2016.html

Onty
Mugi, veo que van bien, la pega que es una de mis diez "posi hormiga" quiero esto para el elefante, jaja

Es que lo quires todo! jaja Hoy a a conformarse con ONTY, que igual un día la hormiga se convierte ni que sea en hámster!

EBIO a 1,90 .....tentador ....😉